Sumitomo Dainippon Pharma (4506) posts record profit, lifts earnings forecast
Sumitomo Dainippon Pharma Co., Ltd. shares climbed 4.8% on Tuesday, 17 June 2026, after the Japanese pharmaceutical firm announced record net profit for fiscal year 2025 and an upward revision to its fiscal year 2026 earnings forecast. The stock is currently trading at ¥1,487, up from its previous close of ¥1,418.
The significant increase in profit for fiscal year 2025, reaching ¥106.9 billion, was primarily attributed to robust sales of its drugs ORGOVYX and GEMTESA in the United States. This performance contributed to a 13.7% rise in revenue. The company also benefited from better-than-expected GEMTESA sales in North America and a favourable yen depreciation, prompting the revised forecast for the fiscal year ending March 2026.
These positive developments have been the main drivers pushing the company's stock higher during today's trading session.
Why Sumitomo Pharma's Raised Forecast Signals Strong Performance
Sumitomo Dainippon Pharma Co., Ltd. is a Japanese pharmaceutical company engaged in the research and development, manufacturing, and sale of pharmaceuticals. It primarily focuses on highly specialised fields such as neuropsychiatry, oncology, and regenerative and cellular medicine. Medicines delivered to patients via doctors' prescriptions form the core of its revenue. It can be said that the company contributes to improving people's health and quality of life by creating innovative therapeutic drugs.
The main driver behind today's share price increase is the company's achievement of a record net profit of ¥106.9 billion in the 2025 fiscal year, and its subsequent upward revision of the earnings forecast for the fiscal year ending March 2026. This is a result of sales of key products, particularly the prostate cancer treatment ORGOVYX and the overactive bladder treatment GEMTESA, significantly exceeding initial expectations in the US market. Such strong performance, surpassing market expectations, serves to boost investor confidence in the company's future prospects.
In response to these positive developments, Sumitomo Pharma's shares are trading today at ¥1,487, marking a 4.8% increase from yesterday's closing price of ¥1,418.
This is akin to a marathon runner significantly beating their personal best during a race, and then further revising their target time upwards for the next competition. Spectators and sponsors would place great expectations on the athlete's hidden potential and future success, with their support and enthusiasm growing even stronger.
Sumitomo Dainippon Pharma Co., Ltd.
Sumitomo Pharma Co., Ltd. (4506), a subsidiary of Sumitomo Chemical Company, Limited, operates in the Healthcare sector, specialising in Drug Manufacturers - Specialty & Generic. The Japanese pharmaceutical firm develops and markets a diverse portfolio of products, including treatments for Parkinson's disease, depression, and type 2 diabetes, alongside atypical antipsychotics and carbapenem antibiotics. Beyond pharmaceuticals, Sumitomo Pharma manufactures food ingredients such as polysaccharides and seasonings, as well as chemical product materials for personal care, coatings, and electronics. The company also supplies veterinary medicines for companion animals and livestock. With a global presence spanning Japan, North America, China, and other international markets, Sumitomo Pharma engages in various strategic partnerships, including collaborations with Healios K.K., Keio University, and Otsuka Pharmaceutical Co., Ltd. The company was founded in 1897 and is headquartered in Osaka, Japan.